687
Participants
Start Date
December 10, 2013
Primary Completion Date
August 12, 2016
Study Completion Date
November 3, 2016
Sofosbuvir
Sofosbuvir 400 mg tablet administered orally once daily
RBV
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
PEG
Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
Beijing
Chongqing
Fujian
Guangdong
Guangxi
Hainan
Hebei
Hubei
Hunan
Jiangxi
Jilin
Jin’an
Liaoyang
Shanghai
Sichuan
Yunnan
Zhejiang
Hong Kong
Shatin
Incheon
Seongnam-si
Ansan-si
Bucheon-si
Busan
Daegu
Seoul
Chang-hua
Kaohsiung City
Keelung
Taichung
Tainan City
Taipei
Taoyuan District
Hanoi
Ho Chi Minh City
Lead Sponsor
Gilead Sciences
INDUSTRY